Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Citigroup Inc. (C) Price & Performance

Bio-Rad Laboratories, Inc. Class A Common StockTrade

Citigroup Inc.Trade

Price performance (Past 24H)

Key statistics

Bio-Rad Laboratories, Inc. Class A Common Stock vs Citigroup Inc. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.02B), while Citigroup Inc. trades at $134.3 (market cap $239.99B). The key difference: Citigroup Inc. is far larger — about 29.9× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Citigroup Inc. pays a 1.71% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.

	BIO	C
Market Cap	$8.02B	$239.99B
Sector	Health	Financials
52-Week High	$339.75	$145.67
52-Week Low	$241.71	$90.02
Enterprise Value	$7.84B	—
Dividend Yield	—	1.71%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bio-Rad Laboratories, Inc. Class A Common Stock

No Aura AI signal available yet.

Citigroup Inc.

Citigroup (C) trades at $140.70, up 0.07% on the day, with a bullish technical outlook and strong Q2 2026 earnings beats. Revenue growth accelerated to $85.21B in 2025, with net income margin improving to 16.78%. The stock is supported by positive analyst sentiment, with 59% recommending Buy and a consensus price target of $157.25. Recent news highlights robust trading and investment banking performance driving the best quarterly results in a decade.

The outlook remains positive given earnings momentum and strategic investments, but risks include volatile cash flows from operations and high leverage. Upside potential exists if the company sustains revenue growth and improves operational efficiency, though macroeconomic sensitivity and competitive pressures could limit gains.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

BIO

View details →

Citigroup beats Q2 earnings estimates with $24.77B revenue and $3.15 EPS, driven by strong trading and banking.Tony Dante · 14 hours agoBullish Citigroup posts strong Q2 with 14% revenue growth, 61% EPS jump, and boosts dividends by 12%.Seeking Alpha · 18 hours agoBullish Citigroup beats Q2 revenue estimates on strong trading and investment banking resultsProactive Investors · 22 hours agoBullish View details →

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

About Citigroup Inc.

Citigroup Inc. is a diversified financial services holding company that provides a broad range of financial services to consumer and corporate customers. The Company services include investment banking, retail brokerage, corporate banking, and cash management products and services. Citigroup serves customers globally.